CrewCrew
FeedSignalsMy Subscriptions
Get Started
Bio tech company updates

Bio tech company updates — 11/13/2026

  1. Signals
  2. /
  3. Bio tech company updates

Bio tech company updates — 11/13/2026

Bio tech company updates|November 13, 2026(4h ago)1 min read8.4AI quality score — automatically evaluated based on accuracy, depth, and source quality
0 subscribers

This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.

Korean biotech news in the past 24 hours spans new clinical-trial testing capacity at GCCL and Alteogen’s planned first appearance at the Jefferies Global Healthcare Conference. Officials also pledged stronger biotech R&D support and faster drug approvals, while forum speakers called for a closer drug-development alliance.

Key Findings

  • GCCL is installing a BD FACSDiscover A7 flow cytometer to expand immune-cell analysis services for clinical trials; the report describes it as a first for Korea’s clinical-trial testing industry.
  • Alteogen said it will attend the 2026 Jefferies Global Healthcare Conference in London from Nov. 16 to 19, marking its first participation.
  • Korean officials pledged increased biotech R&D investment and faster drug approvals, with the approval timeline described as cut to 240 days.
  • Speakers at the 2026 Biomedical Forum urged a drug-development alliance linking biotech ventures, pharmaceutical companies, hospitals and government.

Details

GCCL is adding the BD FACSDiscover A7 flow cytometer as it expands immune-cell analysis for clinical-trial testing. The report characterizes the installation as the first of its kind in Korea’s clinical-trial testing industry.

Image accompanying the report on GCCL’s clinical-trial immune-cell analysis expansion
Image accompanying the report on GCCL’s clinical-trial immune-cell analysis expansion

Alteogen announced that it will take part in the Jefferies Global Healthcare Conference for the first time. The London conference is scheduled for Nov. 16–19, 2026.

Image accompanying the report on Alteogen’s planned Jefferies conference participation
Image accompanying the report on Alteogen’s planned Jefferies conference participation

At the 5th Seoul Economic Daily Biomedical Forum, Korean officials pledged increased R&D investment in biotechnology and faster drug approvals. The report says the approval timeline has been cut to 240 days.

Image accompanying the report on Korea’s biotech R&D and drug-approval pledges
Image accompanying the report on Korea’s biotech R&D and drug-approval pledges

A separate forum report describes calls for a drug-development alliance connecting biotech ventures, drugmakers, hospitals and government. The proposal centers on linking participants across the development process, from laboratory research through manufacturing.

Image accompanying the report on a proposed drug-development alliance
Image accompanying the report on a proposed drug-development alliance


Sources

en.sedaily.com

Korean Biotechs Head to BIO-Europe to Pitch Obesity, Cancer Drugs - Seoul Economic Daily

en.sedaily.com

GCCL Adds Advanced Immune Cell Analyzer to Expand Clinical Trial Testing - Seoul Economic Daily

en.sedaily.com

Korea Vows Faster Drug Approvals, Bigger R&D Push for Biotech - Seoul Economic Daily

en.sedaily.com

Alteogen Joins Jefferies Healthcare Conference for First Time - Seoul Economic Daily

en.sedaily.com

Hanmi Executive: Korea Must Out-Design China

en.sedaily.com

en.sedaily.com

en.sedaily.com

en.sedaily.com

en.sedaily.com

en.sedaily.com

en.sedaily.com

en.sedaily.com

This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.

Explore related topics
  • QWhat are the capabilities of the BD FACSDiscover A7?
  • QWhat is Alteogen planning to present in London?
  • QHow will the new 240-day approval process work?
  • QWhat are the next steps for the drug alliance?

Powered by

CrewCrew

Sources

Want your own AI intelligence feed?

Create custom signals on any topic. AI curates and delivers 24/7.